Premenstrual dysphoric syndrome (PMDS) is a severe form of Premenstrual syndrome (PMS), which is a disabling disease for many women. It is a quiet, hidden endemic disease, from which not only women but also men suffer from. One of twenty women (3-5 % of all women) suffers from PMDS all around the world. It can cause depression, anxiety and aggressiveness, which can in extreme cases lead to lack of control. Some women describe it as “being in hell”.

A hormone called Allopregnanolone, which is released by ovaries usually inhibits brain activities, but in the women who suffer from PMDS it has the opposite effect; it over-activates their brain and causes the patient to get depression, anxiety and aggressiveness.


To assess whether a substance called Isoallopregnanolone (ISO) can block the hormone Allopregnanolone.


The study investigated the impact of ISO in preventing the Allopregnanolone, in order to treat PMDS, and found that Allopregnanolone was successfully blocked by ISO and the results are very satisfactory.

PMDS could potentially be managed by ISO.